July 15, 2014

Helix BioPharma Corp Initiates Enrollment of Ninth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 (PDF)

AURORA, ON–(Marketwired – Jul 15, 2014) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the ninth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland (“LDOS002”). This follows completion of the first treatment cycle in the three patients enrolled in the
eighth dose level cohort, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee.